LLM returned non-JSON response. Review the filing manually.
Price Chart
Executive Summary
{ "summary": "Lixte Biotechnology announced interim results from a Phase 1b trial combining its PP2A inhibitor LB-100 with Dostarlimab in ovarian clear-cell carcinoma, showing a 40% disease control rate and promising overall survival trends. The data support expansion to a higher-dose cohort, marking clinical progress for a company with no current revenue.", "sentiment": "mixed", "impactScore": 6, "confidence": "medium", "keyFacts": [ "Presented interim results from a Phase 1b tria
Financial Impact
Unknown
Risk Factors
- Analysis may be incomplete
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 16w ago | 8-K | $7.29 | awaiting T+1 | — | — |
Jun 18, 2026 18w ago | 8-K | $7.48 $7.30 | ▼ −2.41% | ▼ −0.95% | — |
Jun 16, 2026 18w ago | 8-K | $6.96 $7.61 | ▲ +9.34% | ▲ +8.56% | — |
Jun 12, 2026 19w ago | Press Release | $6.19 $6.72 | ▲ +8.56% | ▲ +6.80% | — |
Jun 4, 2026 20w ago | 8-K | $7.00 $6.65 | ▲ +5.00% | ▲ +5.23% | — |
Jun 4, 2026 20w ago | 424B5 | $7.00 $6.65 | ▲ +5.00% | ▲ +5.23% | — |
Jun 1, 2026 21w ago | 8-K | $7.21 $7.04 | ▼ −2.36% | ▼ −2.50% | — |
May 14, 2026 23w ago | Press Release | $5.16 $4.70 | ▼ −8.91% | ▼ −8.85% | — |
Apr 17, 2026 27w ago | 8-K | $3.44 $3.48 | ▲ +1.16% | ▲ +1.82% | — |
Apr 13, 2026 28w ago | Press Release | $2.93 $2.91 | ▼ −0.68% | ▼ −1.89% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers